Biogen Labs is seeking FDA approval for a new Alzheimer's treatment that slowed cognitive decline 27% in early trials. See potential bias and similarities in coverage from AP, axios, and nypost:
in slowing cognitive decline. The treatment, named Lecanemab, is being developed by Cambridge-based Biogen and Tokyo-based Eisai. Shares in both companies, and other companies researching the disease, jumped after results were announced.that harden into plaque that researchers believe is a contributor to Alzheimer’s. Early results showed that Lacanemab reduced cognitive decline by 27% after 18 months of treatment.
Biogen’s last attempt at an Alzheimer's treatment, called Aduhelm, effectively failed at market last year due to its $56,000 annual price tag and its unproven effectiveness. The key difference between last year’s Aduhelm and this year’s Lecanemab is that Aduhelm targets proteins already hardened into plaque, and Lecanemab targets proteins not yet hardened. Eisai has said that Lecanemab’s annual price tag will fall somewhere between $9,249 and $35,605.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Axios Today on Apple Podcasts☝️ 1 big thing: More than 1 million Floridians lost power after Hurricane Ian made landfall • Plus: low income Americans struggle to afford hurricane prep • And: Russia looks to annex parts of Ukraine 🎧 Listen to Axios Today:
Leer más »
Alzheimer's drug slows progression of cognitive decline in clinical trial, drugmakers say | CNNA monoclonal antibody treatment for Alzheimer's disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday.
Leer más »
Alzheimer's drug slowed progression of the disease in Phase 3 trialThe Japanese drugmaker Eisai said Tuesday its experimental drug for Alzheimer’s disease helped slow cognitive decline in patients in the early stages of the illness.
Leer más »
Biogen shares soar on Alzheimer's drug developmentsA study found that Biogen's Alzheimer's drug lecanemab reduced cognitive and functional decline by 27% compared to a placebo over an 18-month period.
Leer más »
Alzheimer’s Drug Slowed Rate of Decline: New StudyThe drug reduced cognitive decline by 27 percent in people who received the drug compared to a placebo, the study found.
Leer más »